Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization.

Braun M, Stomper J, Boehm D, Vogel W, Scheble VJ, Wernert N, Shaikhibrahim Z, Fend F, Kristiansen G, Perner S.

J Mol Diagn. 2012 Jul;14(4):322-7. doi: 10.1016/j.jmoldx.2012.01.017.

PMID:
22642898
2.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004.

3.

Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L.

Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005.

PMID:
23850495
4.

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S.

Mod Pathol. 2010 Aug;23(8):1061-7. doi: 10.1038/modpathol.2010.87.

5.

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N.

Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989.

6.

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Böhm D, Scheble V, Sotlar K, Fend F, Tan SH, Dobi A, Kristiansen G, Wernert N, Perner S.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9. doi: 10.1038/pcan.2011.67.

PMID:
22231490
7.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150.

8.

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.

Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.

Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193.

9.

ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.

Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H, Magi-Galluzzi C.

Virchows Arch. 2011 Oct;459(4):441-7. doi: 10.1007/s00428-011-1128-4.

PMID:
21773753
10.

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ.

Am J Surg Pathol. 2011 Jul;35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761.

11.

Antibody-based detection of ERG rearrangement-positive prostate cancer.

Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA.

Neoplasia. 2010 Jul;12(7):590-8.

12.

Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.

Neoplasia. 2006 Jun;8(6):465-9.

13.

A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.

Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R, Sollie T, Helenius G, Andersson SO, Demichelis F, Andrén O, Rubin MA.

Appl Immunohistochem Mol Morphol. 2014;22(2):136-41. doi: 10.1097/PDM.0b013e31829e0484.

PMID:
24517914
14.

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.

15.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

PMID:
17385188
16.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927.

17.

Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.

Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S.

Histopathology. 2011 Jun;58(7):1028-36. doi: 10.1111/j.1365-2559.2011.03862.x.

PMID:
21707704
18.

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.

Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA.

BJU Int. 2011 Feb;107(3):477-85. doi: 10.1111/j.1464-410X.2010.09470.x.

19.

Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.

Barros-Silva JD, Ribeiro FR, Rodrigues A, Cruz R, Martins AT, Jerónimo C, Henrique R, Teixeira MR.

Genes Chromosomes Cancer. 2011 Aug;50(8):662-71. doi: 10.1002/gcc.20888.

PMID:
21584900
20.

TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.

Cancer Biol Ther. 2009 Jan;8(2):125-30.

PMID:
19029822
Items per page

Supplemental Content

Support Center